Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* In good general health, as determined by physical examination, laboratory screening, and review of medical history~* Available for the duration of the study, approximately 26 weeks post-vaccination~* Willing to participate in the study as evidenced by signing the informed consent document~* Female participants of childbearing potential must be willing to use effective contraception for the duration of the trial. More information on this criterion can be found in the protocol.~Exclusion Criteria:~* Pregnant or breastfeeding~* Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies~* Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the person's ability to understand and cooperate with the requirements of the study~* Screening laboratory values of Grade 1 or above for absolute neutrophil count (ANC), alanine aminotransferase (ALT), and serum creatinine, as defined in the protocol~* Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a person participating in the study or would render the person unable to comply with the study~* Any significant alcohol or drug abuse in the 12 months before study entry which has caused medical, occupational, or family problems, as indicated by medical history~* History of a severe allergic reaction or anaphylaxis~* Severe asthma (emergency room visit or hospitalization in the 6 months before study entry)~* HIV infection, by screening and confirmatory assays~* Hepatitis C virus (HCV) infection, by screening and confirmatory assays~* Hepatitis B virus (HBV) infection, by Hepatitis B surface antigen (HBsAg) screening~* Any known immunodeficiency syndrome~* Use of anticoagulant medications~* Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 42 days prior to or following vaccination; immunosuppressive dose of corticosteroids is defined as 10 mg or more of prednisone equivalent per day for 14 days or longer~* Receipt of a live vaccine within 28 days or a killed vaccine within the 14 days prior to vaccination or anticipated receipt of any vaccine during the 42 days following vaccination~* Absence of spleen~* Receipt of blood products in the 6 months before study entry, including transfusions or immunoglobulin or anticipated receipt of any blood products or immunoglobulin during the 42 days following vaccination~* History or serologic evidence of previous dengue virus infection or other flavivirus infection (e.g., yellow fever virus, St. Louis encephalitis, West Nile virus)~* Previous receipt of a flavivirus vaccine (licensed or experimental)~* Anticipated receipt of any investigational agent in the 42 days before or after vaccination~* Has definite plans to travel to a dengue endemic area during the study~* Refusal to allow storage of specimens for future research~Inclusion Criteria for Substudy:~* Receipt of vaccine at first vaccination~* In good general health, as determined by physical examination and review of medical history~* Available for the duration of the study, approximately 6 months post-vaccination~* Willing to participate in the study as evidenced by signing the informed consent document~* Female participants of childbearing potential must be willing to use effective contraception for the duration of the trial. More information on this criterion can be found in the protocol.~Exclusion Criteria for Substudy:~* Pregnant or breastfeeding~* Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies~* Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the person's ability to understand and cooperate with the requirements of the study~* Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a person participating in the study or would render the person unable to comply with the study~* Any significant alcohol or drug abuse in the past 12 months which has caused medical, occupational, or family problems, as indicated by medical history~* History of a severe allergic reaction or anaphylaxis~* Severe asthma (emergency room visit or hospitalization within the last 6 months)~* HIV infection, by screening and confirmatory assays~* Hepatitis C virus (HCV) infection, by screening and confirmatory assays~* Hepatitis B virus (HBV) infection, by Hepatitis B surface antigen (HBsAg) screening~* Any known immunodeficiency syndrome~* Use of anticoagulant medications~* Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 42 days prior to or following vaccination; immunosuppressive dose of corticosteroids is defined as 10 mg or more of prednisone equivalent per day for 14 days or longer~* Receipt of a live vaccine within 28 days or a killed vaccine within the 14 days prior to vaccination or anticipated receipt of any vaccine during the 42 days following vaccination~* Absence of spleen~* Receipt of blood products within the past 6 months, including transfusions or immunoglobulin or anticipated receipt of any blood products or immunoglobulin during the 42 days following vaccination~* Anticipated receipt of any other investigational agent in the 42 days before or after vaccination~* Has definite plans to travel to a dengue endemic area during the study~* Refusal to allow storage of specimens for future research

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- TetraVax-DV Vaccine-Admixture 1 (Type: EXPERIMENTAL): Participants will receive the TetraVax-DV admixture 1 vaccine.
- TetraVax-DV Vaccine-Admixture 2 (Type: EXPERIMENTAL): Participants will receive the TetraVax-DV admixture 2 vaccine.
- TetraVax-DV Vaccine-Admixture 3 (Type: EXPERIMENTAL): Participants will receive the TetraVax-DV admixture 3 vaccine.
- TetraVax-DV Vaccine-Admixture 4 (Type: EXPERIMENTAL): Participants will receive the TetraVax-DV admixture 4 vaccine.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive the placebo.
- TetraVax-DV Vaccine-Admixture 5 (Type: EXPERIMENTAL): Participants will receive the TetraVax-DV admixture 5 vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete